Sat, Feb 28, 2015, 11:01 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aethlon Medical, Inc. Message Board

  • robert.vince robert.vince Sep 12, 2013 8:37 AM Flag

    Aethlon Medical Announces Launch of Exosome Sciences Subsidiary

    Aethlon Medical, Inc. (AEMD), today announced the formal launch of Exosome Sciences, Inc. (ESI), a wholly-owned subsidiary previously established by Aethlon to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. Exosomes produced by diseased cells represent an optimal diagnostic target as they are shed into bodily fluids such as urine and blood where they can be easily accessed. Exosomes transport specific disease-origin markers that provide the basis for ESI to establish non-invasive liquid biopsies to diagnose and monitor a wide-range of disease conditions.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • So RV, how does AEMD do this with virtually no financial resources? I guess they just create a sub, hire no one, but get some press out of it.

      Sentiment: Hold

    • Aethlon Chairman and CEO, Jim Joyce stated, "As a therapeutic organization, our primary focus is the clinical advancement and future commercialization of the Aethlon Hemopurifer┬« in the United States and abroad. With this mind, our objective with ESI is to transform a currently dormant and unvalued diagnostic asset into a stand-alone organization that contributes measurable asset value to Aethlon shareholders, yet does not dilute our team's focus away from advancing first-in-class therapeutic devices. It also became clear that the launch of ESI might allow us to leverage recent valuations that have been awarded to molecular diagnostic organizations with novel technology strategies."

      Aethlon disclosed that ESI's research facility is being established within a CLIA certified laboratory located in Langhorne, Pennsylvania. The facility is adjacent to the Philadelphia/New Jersey I-95 corridor, which is the home for numerous U.S. biopharmaceutical organizations, including Merck and Johnson & Johnson. The introduction of key ESI researchers who will lead the development and commercialization of next-generation diagnostics will occur through follow-on disclosures.

      • 1 Reply to robert.vince
      • At present, Aethlon is preparing to launch the first U.S. studies of the Hemopurifier┬« as a therapy to address hepatitis c virus (HCV) based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). The Hemopurifier is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens, including exosomes from circulation. Exosomes enhance disease progression of viral infections and in cancer trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance.

 
AEMD
0.19-0.02(-9.09%)Feb 27 3:58 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.